An observational, retrospective study of Lobeglitazone in poorly controlled type 2 diabetics with insulin resistance
Latest Information Update: 09 Jan 2018
Price :
$35 *
At a glance
- Drugs Lobeglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 09 Jan 2018 New trial record
- 08 Dec 2017 Results presented at the 2017 Congress of the International Diabetes Federation